Rubicon Research Share Price

1,368.8017.21 (1.28%)

Live
As On: 17 Jun, 2026, 10:11 AM IST
As On: 17 Jun, 2026, 10:11 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	1,348.40
High	1,371.90
Low	1,330.90
Prev Close	1,351.60
Volume	84,733
VWAP(₹)	1,353.09

Share Price	Value
Today/Current/Last	1,368.801,369.95
Previous Day	1,351.601,355.00

Rubicon Research Share Recommendations

Mean recosCurrent

STRONG BUY

2 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	2	2	2	2
Buy	-	-	-	-
Hold	-	-	-	-
Sell	-	-	-	-
Strong Sell	-	-	-	-
# Analysts	2	2	2	2

View all Stock Recommendations

News & Analysis

Rubicon Research shares can rally 22%, says Motilal Oswal after initiating with ‘Buy’ rating
News
Buy, Sell or Hold: Motilal Oswal initiates buy on Rubicon Research; Morgan Stanley recommends overweight on Aditya Birla Capital
News
Healthy start! Rubicon Research shares list at 28% premium over IPO price
News
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcements

View all Rubicon Research Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	516.53	479.32	412.72	356.95	361.76
Total Income Growth (%)	7.76	16.14	15.62	-1.33	15.25
Total Expenses	407.48	378.96	329.59	286.77	298.85
Total Expenses Growth (%)	7.53	14.98	14.93	-4.04	18.16
EBIT	109.05	100.36	83.12	70.17	62.91
EBIT Growth (%)	8.66	20.74	18.46	11.54	3.18
Profit after Tax (PAT)	76.79	72.80	53.85	43.30	36.25
PAT Growth (%)	5.48	35.18	24.37	19.47	-4.80
EBIT Margin (%)	21.11	20.94	20.14	19.66	17.39
Net Profit Margin (%)	14.87	15.19	13.05	12.13	10.02
Basic EPS (₹)	4.66	4.46	3.49	2.81	2.35

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	393.46	306.01	337.98	279.46	312.78
Total Income Growth (%)	28.58	-9.46	20.94	-10.65	26.53
Total Expenses	293.88	248.98	267.14	223.18	248.07
Total Expenses Growth (%)	18.04	-6.80	19.70	-10.03	31.32
EBIT	99.58	57.04	70.84	56.28	64.71
EBIT Growth (%)	74.59	-19.48	25.86	-13.02	10.98
Profit after Tax (PAT)	70.02	37.18	45.81	35.15	40.27
PAT Growth (%)	88.32	-18.84	30.33	-12.70	5.33
EBIT Margin (%)	25.31	18.64	20.96	20.14	20.69
Net Profit Margin (%)	17.80	12.15	13.55	12.58	12.87
Basic EPS (₹)	4.25	2.28	2.97	2.28	2.61

	FY 2026	FY 2025	FY 2024
Total Revenue	1,761.68	1,296.22	872.39
Total Revenue Growth (%)	35.91	48.58	108.21
Total Expenses	1,441.15	1,101.70	769.53
Total Expenses Growth (%)	30.81	43.16	78.94
Profit after Tax (PAT)	246.74	134.36	91.01
PAT Growth (%)	83.64	47.63	-
Operating Profit Margin (%)	20.67	18.01	15.70
Net Profit Margin (%)	14.06	10.46	10.65
Basic EPS (₹)	15.52	8.82	5.98

	FY 2026	FY 2025	FY 2024	FY 2023
Total Revenue	1,316.91	1,093.52	656.94	435.87
Total Revenue Growth (%)	20.43	66.46	50.72	4.42
Total Expenses	1,064.14	870.24	622.87	417.60
Total Expenses Growth (%)	22.28	39.72	49.15	4.27
Profit after Tax (PAT)	188.17	167.54	24.35	12.72
PAT Growth (%)	12.31	588.04	91.44	-23.76
Operating Profit Margin (%)	21.72	23.98	10.24	9.07
Net Profit Margin (%)	14.40	15.60	3.86	3.12
Basic EPS (₹)	11.83	11.00	1.60	25.09

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 2.4% of its operating revenues towards interest expenses and 14.61% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024
Total Assets	2,326.71	1,451.43	1,109.49
Total Assets Growth (%)	60.30	30.82	47.99
Total Liabilities	1,037.89	910.45	724.49
Total Liabilities Growth (%)	14.00	25.67	56.37
Total Equity	1,288.82	540.99	385.00
Total Equity Growth (%)	138.24	40.51	34.44
Current Ratio (x)	2.01	1.35	1.33
Total Debt to Equity (x)	0.20	0.73	1.03
Contingent Liabilities	0.00	438.65	145.92

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Total Assets	1,975.50	1,340.94	1,016.60	867.67
Total Assets Growth (%)	47.32	31.90	17.16	27.91
Total Liabilities	622.23	673.15	540.73	424.17
Total Liabilities Growth (%)	-7.56	24.49	27.48	69.85
Total Equity	1,353.27	667.79	475.87	443.50
Total Equity Growth (%)	102.65	40.33	7.30	3.47
Current Ratio (x)	3.10	1.61	1.32	1.85
Total Debt to Equity (x)	0.19	0.59	0.83	0.72
Contingent Liabilities	0.00	553.15	151.77	50.54

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024
Net Cash flow from Operating Activities	205.05	159.18	21.01
Net Cash used in Investing Activities	-409.72	-64.81	-68.51
Net Cash flow from Financing Activities	283.07	-39.81	43.55
Net Cash Flow	80.68	54.37	-3.82
Closing Cash & Cash Equivalent	185.65	104.98	50.61
Closing Cash & Cash Equivalent Growth (%)	76.85	107.44	-7.02
Total Debt/ CFO (x)	1.26	2.47	18.87

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Net Cash flow from Operating Activities	38.71	29.65	83.20	-79.02
Net Cash used in Investing Activities	-271.79	-10.03	-130.49	-33.95
Net Cash flow from Financing Activities	296.72	-34.05	45.86	123.65
Net Cash Flow	65.93	-14.62	-1.29	12.19
Closing Cash & Cash Equivalent	91.78	25.85	40.47	41.76
Closing Cash & Cash Equivalent Growth (%)	255.03	-36.12	-3.10	41.23
Total Debt/ CFO (x)	6.70	13.26	4.76	-4.02

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 409.72 cr for investing activities which is an YoY increase of 532.2%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024
Return on Equity (%)	19.14	24.83	23.63
Return on Capital Employed (%)	24.32	34.76	24.97
Return on Assets (%)	10.60	9.25	8.20
Interest Coverage Ratio (x)	9.67	7.28	5.54
Asset Turnover Ratio (x)	0.93	1.00	0.92
Price to Earnings (x)	51.81	-	-
Price to Book (x)	9.90	-	-
EV/EBITDA (x)	31.05	-	-
EBITDA Margin (%)	23.25	20.85	20.27

Annual	FY 2026	FY 2025	FY 2024	FY 2023
Return on Equity (%)	13.90	25.08	5.11	2.86
Return on Capital Employed (%)	18.68	34.23	11.03	6.78
Return on Assets (%)	9.52	12.49	2.39	1.46
Interest Coverage Ratio (x)	10.38	8.45	3.26	3.73
Asset Turnover Ratio (x)	0.79	0.91	0.67	0.53
Price to Earnings (x)	68.03	-	-	-
Price to Book (x)	9.42	-	-	-
EV/EBITDA (x)	39.70	-	-	-
EBITDA Margin (%)	24.61	26.96	15.78	17.13

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance
No Data Available
Stock Performance
No Data Available

Category	No. of Shares	Percentage	% Change QoQ
Promoters	9,88,28,360	59.86 %	-0.13
Pledge	0	0.00 %	0.00
FII	1,24,43,308	7.54 %	-0.45
DII	1,65,35,056	10.02 %	0.57
MF	1,17,79,842	7.14 %	0.52
Others	3,72,85,400	22.58 %	0.00

Category	Mar 2026	Dec 2025
Promoters	59.86	59.99
Pledge	0.00	0.00
FII	7.54	7.99
DII	10.02	9.44
Mutual Funds	7.14	6.61
Others	22.58	22.58

Mutual Funds Ownership

MF Ownership as on 31 May 2026

Kotak Midcap Direct-G
Equity: Mid Cap
3
- 379.96
  Amount Invested (in Cr.)
- 0.58681061%
  % of AUM
- 0.00
  % Change (MoM basis)
Motilal Oswal Small Cap Direct-G
Equity: Small Cap
- 247.80
  Amount Invested (in Cr.)
- 3.8%
  % of AUM
- 0.55
  % Change (MoM basis)
Bajaj Finserv Flexi Cap Direct-G
Equity: Flexi Cap
- 105.51
  Amount Invested (in Cr.)
- 1.47%
  % of AUM
- 9.31
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
Final
150%
May 29, 2026
Board Meeting
Audited Results & Final Dividend
May 22, 2026
General Meeting
-
Feb 13, 2026
Board Meetings
Announced on Meeting on
May 22, 2026 May 29, 2026
Audited Results & Final Dividend
Jan 27, 2026 Feb 03, 2026
Quarterly Results
Nov 07, 2025 Nov 13, 2025
Quarterly Results
Dividends
Announced on Ex-Date Dividend%
May 29, 2026 - 150%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
Feb 13, 2026 Mar 17, 2026
-
Nov 07, 2025 Dec 09, 2025
-

Announced on	Meeting on
May 22, 2026	May 29, 2026
Audited Results & Final Dividend
Jan 27, 2026	Feb 03, 2026
Quarterly Results
Nov 07, 2025	Nov 13, 2025
Quarterly Results

Announced on	Ex-Date	Dividend%
May 29, 2026	-	150%

Announced on	Meeting on
Feb 13, 2026	Mar 17, 2026
-
Nov 07, 2025	Dec 09, 2025
-

About Rubicon Research

Rubicon Research Ltd., incorporated in the year 1999, is a Small Cap company (having a market cap of Rs 22,313.85 Crore) operating in Pharmaceuticals sector.

Rubicon Research Ltd. key Products/Revenue Segments include Sale of Products, Export Incentives, Royalty Income and Research & Development for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 516.52 Crore, up 7.76 % from last quarter Total Income of Rs 479.32 Crore and up 42.78 % from last year same quarter Total Income of Rs 361.76 Crore. Company has reported net profit after tax of Rs 76.78 Crore in latest quarter.

The company’s top management includes Mr.Venkat Changavalli, Ms.Pratibha Pilgaonkar, Mr.Parag Suganchand Sancheti, Mr.Anand Agarwal, Mr.Shantanu Rastogi, Mr.Varun Talukdar, Mr.Kumarapuram Gopalakrishnan Ananthakrishnan, Mr.Milind Anil Patil, Mr.Nitin Jajodia, Ms.Deepashree Tanksale. Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-03-2026, the company has a total of 16.51 Crore shares outstanding.

Rubicon Research Share Price Today is Rs. 1368.80. On previous day, the Rubicon Research Share Price (NSE) closed at Rs. 1344.4, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 59.86% of the stake in Rubicon Research shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Rubicon Research stocks was 7.54% as compared to 7.99% in Dec 2025 with decrease of 0.45%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 10.02% as compared to 9.44% in Dec 2025 with increase of 0.58%. Out of the total DII holdings in Rubicon Research shares 7.14% was held by mutual funds. The rest including public held is 22.58%. Rubicon Research stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Rubicon Research Dividend: Ever since 1999, Rubicon Research dividends has been paid out around 1 times. As on 17 Jun, 2026, 10:11 AM IST, The overall dividend yield for Rubicon Research stands at 0.0%. The last dividend paid was on null (Rs. 1.5). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 14.95.

Rubicon Research Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 516.52 Cr. of sales and 0.0% of quarterly net null, there have been multiple ups and downs in the Rubicon Research stock prices in the past few weeks. For example, Rubicon Research stock price on 9th of June 2026 was around Rs. 1170.5. Rubicon Research share price now stands at an average of Rs. 1368.80. Judging by last week's performance, stock is in up trend.

Rubicon Research has a median target price of Rs. 1175.0 in 12 months by 2 analysts. They have provided a high estimate of Rs. 1190.0 and low estimate of Rs. 1160.0 for Rubicon Research share.

Historical Prices and Performance:
Rubicon Research, incorporated in 1999 is a Mid Cap company (with a market cap of Rs. 22313.85) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Rubicon Research stock was 19.14%, 24.83%, 23.63%, -5.89% and 3.89% respectively.
The Rubicon Research share gave a 3 year return of 0.0% as compared to Nifty 50 which gave a return of 0.0%.
Rubicon Research announced 150.0% final dividend on null.

Key Metrics:
PE Ratio of Rubicon Research is 90.44
Prices/Sales Ratio of Rubicon Research is 7.27
Price/Book Ratio of Rubicon Research is 17.31

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at 90.44 and 17.31 respectively.

Leadership of Rubicon Research :
Deepashree Tanksale is Co. Secretary & Compl. Officer
Nitin Jajodia is Chief Financial Officer
Pratibha Pilgaonkar is Managing Director
Parag Suganchand Sancheti is Executive Director & CEO
Venkat Changavalli is Chairperson & Independent Director
Varun Talukdar is Non Executive Director
Shantanu Rastogi is Non Executive Director
Anand Agarwal is Non Executive Director
Kumarapuram Gopalakrishnan Ananthakrishnan is Independent Director
Milind Anil Patil is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

BSE Healthcare, BSE IPO Index, Nifty IPO

Address

MedOne House, B-75, Road No. 33, Wagle Estate,Thane, Maharashtra - 400604

Contact

investors@rubicon.co.in

www.rubicon.co.in

PE Ratio(x)	91.08
EPS - TTM(₹)	14.95
MCap(₹ Cr.)	22,208.19
MCap Rank	24
PB Ratio(x)	17.31
Div Yield(%)	-
Face Value(₹)	1.00
52W High(₹)	1,400.00
52W Low(₹)	570.75
MCap/Sales	7.27
Beta(1 Month)	-
BV/Share(₹)	78.07

PE Ratio(x)	91.33
EPS - TTM(₹)	14.95
MCap(₹ Cr.)	22,401.35
MCap Rank	24
PB Ratio(x)	17.36
Div Yield(%)	-
Face Value(₹)	1.00
52W High(₹)	1,399.45
52W Low(₹)	571.00
MCap/Sales	7.27
Beta(1 Month)	-
BV/Share(₹)	78.07

1 Day	1.28%
1 Month	42.44%
3 Months	81.97%
1 Year	N.A.
3 Years	N.A.
5 Years	N.A.

1 Day	1.1%
1 Month	42.33%
3 Months	82.13%
1 Year	N.A.
3 Years	N.A.
5 Years	N.A.

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Rubicon Research Share Price

Key Metrics